

Caspase recruitment domain 9, microbiota, and tryptophan metabolism: dangerous liaisons in inflammatory bowel diseases

Bruno Lamas, Mathias L. Richard, Harry Sokol

► **To cite this version:**

Bruno Lamas, Mathias L. Richard, Harry Sokol. Caspase recruitment domain 9, microbiota, and tryptophan metabolism: dangerous liaisons in inflammatory bowel diseases. *Current Opinion in Clinical Nutrition and Metabolic Care*, Lippincott, Williams & Wilkins, 2017, 20 (4), pp.243-247. <10.1097/MCO.0000000000000382>. <hal-01559987>

HAL Id: hal-01559987

<http://hal.upmc.fr/hal-01559987>

Submitted on 11 Jul 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Caspase recruitment domain 9, microbiota and tryptophan metabolism: dangerous liaisons in Inflammatory bowel diseases

Bruno Lamas^{1,2,3,4,5,6}, Mathias L. Richard^{5,6}, Harry Sokol^{1,2,3,4,5,6,7*}

¹Sorbonne University–UPMC Paris, France. ²INSERM ERL 1157, Avenir Team Gut Microbiota and Immunity, Paris, France. ³CNRS UMR 7203, Paris, France. ⁴Laboratoire de BioMolécules (LBM), CHU Saint-Antoine 27 rue de Chaligny, Paris, France. ⁵Micalis Institute, INRA, AgroParisTech, Université Paris–Saclay, Jouy-en-Josas, France. ⁶Inflammation–Immunopathology–Biotherapy Department (DHU i2B), Paris, France. ⁷Department of Gastroenterology, Saint Antoine Hospital, Assistance Publique–Hopitaux de Paris, UPMC, Paris, France.

***Correspondence:** Pr Harry Sokol

Gastroenterology Department

Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75571 Paris CEDEX 12,
France

Tel.: +33 1 49 28 31 71

Fax: +33 1 49 28 31 88

E-mail: harry.sokol@aphp.fr

Abstract

Purpose of review

Inflammatory bowel diseases (IBDs) develop as a result of a combination of genetic predisposition, dysbiosis of the gut microbiota, and environmental influences. Here, we describe an example of how Caspase recruitment domain 9 (CARD9), one of the numerous IBD susceptibility genes, participate to colitis susceptibility by shaping gut microbiota to produce tryptophan metabolites.

Recent findings

Recent study showed that *Card9*^{-/-} mice are more susceptible to colitis as a result of impaired interleukin 22 (IL-22) signaling pathway. Furthermore, aryl hydrocarbon receptor (AhR) ligands from tryptophan metabolism by the gut microbiota participate to intestinal homeostasis by inducing production of IL-22 by intestinal immune cells. These data suggest an interaction between CARD9 and the ability of gut microbiota to produce AhR ligands.

Summary

The microbiota from *Card9*^{-/-} mice fails to metabolize tryptophan leading to defective AhR activation which contributes to the susceptibility of mice to colitis by decreased IL-22 production. These effects were abrogated in the presence of AhR agonist. Reduced production of AhR ligands is also observed in the microbiota from individuals with IBD, particularly in those with *CARD9* risk alleles associated with IBD. Correcting impaired microbiota functions, such as ability to produce AhR ligands, is an attractive strategy in IBD.

Keywords: CARD9, IBD, microbiota, tryptophan.

INTRODUCTION

The gastro-intestinal tract is a complex milieu in which coexist host epithelial and immune cells, a wide array of microorganisms and molecules from food or microbiota metabolism. A functional intestinal barrier is essential to maintain the balance between health and disease. This is accomplished by a tightly regulated process involving multiple cell types. The single layer of epithelial cells forms a physical barrier between the intestinal lumen and the host's lamina propria (LP). Specialized intraepithelial lymphocytes (IELs), such as TCR $\gamma\delta$ cells, are located between epithelial cells and represent a critical first line of defense. In the LP, a variety of immune cells are present (B cells, T cells, macrophages, dendritic cells, and innate lymphoid cells (ILCs)) that participate in the maintenance of intestinal homeostasis. The intestinal immune system plays a crucial role in shaping the microbiota so it can be tolerated by the host.

The human intestinal microbiota is a complex ecosystem composed of more than 10^{11} microorganisms per gram of feces. It plays a crucial role in wide variety of vital functions such as digestion, immune system development, resistance against intestinal pathogens, etc. Indeed, germ-free (GF) mice have defects in intestinal immune system development and function, including in development of gut-associated lymphoid tissue and production of Immunoglobulin A [1*]. Moreover, metabolites derived from commensal bacteria, as the short-chain fatty acids (SCFA), the polyamines and the aryl hydrocarbon receptor (AhR) ligands may regulate immune cells functions via indirect and direct mechanisms [1*]. *Lactobacilli* spp. can metabolize dietary tryptophan in AhR ligands that induce IL-22 production by ILC leading to production of antimicrobial peptides by intestinal epithelial cells which provide resistance for opportunistic pathogens such as *Candida albicans* [2].

In correlation, tryptophan-free diet in mice decreases the production of intestinal antimicrobial peptides that affects the gut microbiota composition and diversity, suggesting that tryptophan metabolism by the gut microbiota play an important role in mucosal homeostasis [3]. Therefore, the complex bilateral interaction between the host and its microbiota has a crucial role in human health. In some circumstances, the tolerance toward the intestinal microbiota is broken, leading to inappropriate immune response and intestinal or extra-intestinal inflammation. This is the case in inflammatory bowel diseases (IBD).

Inflammatory bowel disease (IBD)

IBD include Crohn's disease (CD) and ulcerative colitis (UC) and are characterized by pathological inflammation of the digestive tract. In CD, inflammation affects the entire digestive tract while only the rectum and colon are affected in UC. These diseases have periods of active illness followed by periods of remission whose duration and frequency are patient dependant. IBDs appear most often between the age of 20 and 30 years old. These pathologies modify for the long-term the health-related quality of life of patients and currently these chronic diseases do not have curative treatment. The highest occurrence of IBD is found in the developed countries of North America and Europe but IBD has also emerged in newly industrialized countries as well as Asia and South and Central America. The pathogenesis of IBD is unknown but involves an activation of the gastro-intestinal immune system toward the gut microbiota in genetically susceptible hosts and under the influence of environment. As pointed out above, the composition of the intestinal microbiota affects the host as a whole. In recent studies, anti- or pro-inflammatory microorganisms have been identified: in the mice, segmented filamentous bacteria induce

T helper 17 (Th17) cells in the small intestine which have pro-inflammatory effects [4*]. Other bacteria like *Bacteroides fragilis* [5] and *Feacalibacterium prausnitzii* [6,7*] have anti-inflammatory effects mediated by metabolites production and/or regulatory T cells recruitment. Thus, loss of the fragile equilibrium within this complex ecosystem termed dysbiosis often characterized by a decreased biodiversity, overgrowth of potentially harmful microorganisms and disappearance of protective ones can eventually trigger numerous pathologies, including IBD [8*,9*]. However, it is still unclear whether dysbiosis is a cause or a consequence of these diseases. In addition of the dysbiosis, genetic factors are also suspected in the IBD pathogenesis. More than 160 IBD susceptibility loci have been identified and among them several in the gene CARD9 [10*].

Caspase Recruitment Domain 9 (CARD9)

CARD9 is signaling protein that is highly expressed in myeloid cells and particularly in macrophages and dendritic cells. It is an adapter protein playing a central role for the integration of signals downstream of Pattern Recognition Receptors (PRRs). CARD9 play a major role in the sensing of mycobacteria, bacteria, fungi and virus via different receptors (Mincle, TLR, NOD2 and Dectin respectively). Downstream of CARD9, several pathways are involved including NF- κ B and p38/JNK leading to cytokines production and participating to the elimination of the detected microorganisms. Card9 is thus a key adapter protein for innate immunity toward a wide range of microorganisms including many intestinal commensals and pathogens [11,12,13*,14]. We showed in a previous study that Card9 knockout mice (*Card9*^{-/-}) are more susceptible to dextran sulfate sodium (DSS) – induced colitis which is used to mimic IBD in mice [12]. *Card9*^{-/-} mice exhibited an

impaired immune response with defective expression of IL-6, IL-17, IFN- γ and IL-22 in the colon [12]. IL-22 is involved in mucosal wound healing and it mediates innate antimicrobial resistance in mice by inducing production of antimicrobial peptides, such as Reg3 γ and Reg3 β , by intestinal epithelial cells [15*,16]. Moreover, we have recently showed that intestinal epithelial cell proliferation is reduced and apoptosis is increased after DSS-induced colitis in *Card9*^{-/-} mice [17*]. In these mice, we also observed a decreased colonic expression of Reg3 γ and Reg3 β and an alteration of the bacterial and fungal microbiota [17*]. The major role of IL-22 and some of its target genes Reg3 γ and Reg3 β in the response to bacterial infections suggested that *Card9*^{-/-} gut microbiota might be deeply impacted.

Impact of the *Card9*^{-/-} microbiota in the susceptibility to colitis

Using the linear discriminant analysis effect size (LEfSe) pipeline, we observed several differences in the composition of the fecal bacterial microbiota at baseline in WT and *Card9*^{-/-} mice, including decreases in *Adlercreutzia* (genus), *Allobaculum* (genus), and *Lactobacillus reuteri* in *Card9*^{-/-} mice [17*]. These data confirmed that CARD9 plays an important role in shaping the microbiota but raises questions about the specific role of the microbiota in the hyper-susceptibility to colitis that is observed in *Card9*^{-/-} mice. To address this question, we colonized GF WT mice with the microbiota of WT (WT \rightarrow GF) or *Card9*^{-/-} (*Card9*^{-/-} \rightarrow GF) mice and exposed them to DSS. The transfer of *Card9*^{-/-} microbiota in GF WT mice was sufficient to recapitulate the phenotype observed in *Card9*^{-/-} mice. Indeed, we observed an increased susceptibility to colitis with decreased proliferation and increased apoptosis in intestinal epithelial cell of *Card9*^{-/-} \rightarrow GF mice. Transcriptomic

analysis in the colon showed also a down-expression of IL-22, Reg3 γ and Reg3 β in *Card9*^{-/-}→GF mice. In these animals, decreased production of IL-22 in the colon and in the mesenteric lymph nodes was also observed. No differences in IL-22 amounts were observed in splenocytes, suggesting a gut-limited defect in *Card9*^{-/-}→GF mice [17*]. Several sources of IL-22 have been identified in the gut, including ILCs, natural killer cells, T helper 17 (Th17) and Th22 cells, TCR $\gamma\delta$ cells, and lymphoid tissue inducer (LTi) cells [15*,18]. Flow cytometry analysis of these different cells demonstrated that the microbiota of *Card9*^{-/-} mice is defective in inducing IL-22 production by Th22, NKp46⁺ ILCs, LTi cells, and CD3⁻CD4⁻NKp46⁻ cells in the colon, leading to increased susceptibility to colitis [17*].

Tryptophan metabolism is impaired in *Card9*^{-/-}→GF mice

Recent data have suggested that tryptophan catabolites generated by the microbiota metabolism have a role in mucosal immune responses via the aryl hydrocarbon receptor (AhR) by modulating production of IL-22 [2,19]. AhR is a ligand-activated nuclear transcription factor widely expressed in the body and evolutionarily conserved from invertebrates onwards [20]. In the absence of a ligand, AhR is retained in an inactive complex in the cytoplasm but after ligand binding it translocates into the nucleus where it binds genomic regions containing the dioxin response element (DRE) that regulates expression of target genes. For many years AhR was almost exclusively studied for its role in mediating the toxicity of xenobiotics, and notably of a side product in industrial organic synthesis of herbicides, 2,3,7,8-tetrachlorodibenzo-p-dioxin. Recently, AhR signaling has been shown to be a key player of the immune response, particularly at barrier sites such as

the skin and the intestinal mucosa [20,21**]. Tryptophan can be metabolized either by the gut bacteria into indole derivatives, such as indole-3-acetic acid (IAA) or by host cells into kynurenine (Kyn) via indoleamine 2,3-dioxygenase 1 (IDO1) [2,21**]. Indole derivatives are AhR ligands known to promote local IL-22 production by immune cells [1*,21**]. To determine whether the modulation of AhR activation by the intestinal microbiota is involved in the decreased IL-22 production in our model, we determined the concentration of AhR ligands in the feces of our mice. Production of IAA was impaired in feces of *Card9*^{-/-}→GF mice. Using mice hepatoma cell lines containing a stably integrated DRE-driven firefly luciferase reporter plasmid we found that feces from *Card9*^{-/-}→GF mice were defective in their ability to activate AHR, to a similar extent as that for feces from GF mice [17*]. *Lactobacillus reuteri* can catabolize tryptophan to indole derivatives with AhR agonistic activity and there is preliminary evidence that other species can also produce AhR agonists via unknown pathways [2]. In line with these data, culture supernatants of *L. reuteri* and *Allobaculum* sp., two bacteria with decreased abundance in the *Card9*^{-/-} mice microbiota, strongly activate AhR [17*]. These results suggested that impaired tryptophan metabolism by the microbiota of the *Card9*^{-/-} mice could be associated with, or even be responsible for, the hypersusceptibility of *Card9*^{-/-} mice to colitis. In WT mice, bacterial microbiota analysis allowed us to isolate several strains producing high amounts of AhR ligands including three strains of *Lactobacillus* (*L. murinus*, *L. reuteri* and *L. taiwanensis*). In *Card9*^{-/-}→GF mice, susceptibility of colitis, and IL-22 defect were rescued after treatment with AHR agonist (6-formylindolo(3,2-b)carbazole), or inoculation with the three *Lactobacillus* strains with strong AHR agonist activity. These effects were mediated by AHR, as they were abrogated in the presence of an AHR antagonist (CH223191) [17*].

These results showed that impaired tryptophan metabolism in the microbiota of the *Card9*^{-/-} mice lead to defective AhR activation which contributes to the susceptibility of mice to colitis by reduction of IL-22 production.

Impaired AhR activity and tryptophan metabolites in patients with IBD

To determine whether these findings were relevant to human disease, we analyzed fecal samples from individuals with IBD and healthy subjects for their ability to activate AHR. Impaired AhR activity associated with decreased concentrations of IAA and tryptophan were observed in feces of patients with IBD. These patients were also genotyped for an IBD-associated single-nucleotide polymorphism (SNP) within *CARD9* (rs10781499) [22]. We observed that the risk allele was associated with reduced AhR activation by microbiota-derived metabolites extracted from fecal samples. No association was observed among other major IBD-associated SNP, including those in *NOD2* [17*]. These results suggest a connection between IBD, *CARD9*, and the ability of the microbiota to produce AHR agonists in humans.

Conclusion

These results in human should be confirmed in an independent cohort but indole derivatives, or the microorganisms that produce them, could be used as a supportive therapy in individuals with intestinal dysbiosis to override the defect of tryptophan metabolism by the gut microbiota. In a more general concept, our findings support the notion that abnormal innate immunity, such as defect in *CARD9*, can shape an altered microbiota, which can then modify the host immune response and amplify the dysbiosis in

a vicious cycle leading to the loss of intestinal homeostasis. Therefore, the respective roles of the host factors and the gut microbiota in IBD pathogenesis cannot be completely distinguished. Thus, dysbiosis should neither be considered a cause nor a consequence of IBD, but both simultaneously.

Key points

- Alteration of intestinal microbiota is observed in IBD.
- *CARD9* is one of the identified IBD susceptibility genes.
- *CARD9* has a role in shaping the bacterial and fungal gut microbiota and it is required for the production of AhR ligands by the microbiota.
- Impaired ability of the microbiota to catabolize tryptophan into AhR ligands increased sensitivity to colitis by altering the IL-22 signaling pathway.
- Impaired microbial production of AHR ligands is observed in patients with IBD and correlates with an IBD-associated SNP within *CARD9*.

Acknowledgements

We thank the members of the ANAXEM germ-free platform, the members of the animal facilities of INRA, and T. Ledent of the animal facilities of Saint-Antoine Hospital for their assistance in mouse care; M. Moroldo and J. Lecardonnell from the CRB GADIE core facility for technical assistance in performing the microarray analyses; S. Dumont for technical help in histology and immunochemistry; and C. Aubry, N. M. Breyner, F. Chain, S. Le Guin, C. Cherbuy, N. Lapaque, S. Taleb, B. Ryffel and D. Skurnik for fruitful discussions and technical help. We also thank E. Drouet and the Clinical Research

Assistant team of Unité de Recherche Clinique de l'Est Parisien for their help in obtaining samples from patients with IBD. The cell reporter system to determine AhR activity was provided by Michael S. Denison (University of California, Davis, CA, USA).

Financial Support and Sponsorship

Funding was provided by Equipe ATIP–Avenir 2012, INSERM–ITMO SP 2013 and ECCO grant 2012. HS is an awardee of the European Research Council (ERC-2016-StG-715776).

Conflicts of Interest

None.

References

1. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. *Nat Rev Immunol* 2016; 16:341–52.
* A recent review discussing the interactions between microbiota and host immunity with a focus on specific microbial metabolites and bacterial components.
2. Zelante T, Iannitti RG, Cunha C, *et al.* Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity* 2013; 39:372–85.
3. Hashimoto T, Perlot T, Rehman A, *et al.* ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. *Nature* 2012; 487:477–81.
4. Atarashi K, Tanoue T, Ando M, *et al.* Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells. *Cell* 2015; 163:367–80.
* Interesting study showing that adhesion of SFB to intestinal epithelial cells is essential for the induction of Th17 cells.
5. Telesford KM, Yan W, Ochoa-Reparaz J, *et al.* A commensal symbiotic factor derived from *Bacteroides fragilis* promotes human CD39(+)Foxp3(+) T cells and Treg function. *Gut Microbes* 2015; 6:234–42.
6. Sarrabayrouse G, Bossard C, Chauvin J-MM, *et al.* CD4CD8 $\alpha\alpha$ lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. *PLoS Biol* 2014; 12:e1001833.

7. Rossi O, Berkel LA van, Chain F, *et al.* Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. *Sci Rep* 2016; 6:18507.
*A recent study investigating the immunomodulatory properties of different F. prausnitzii strains and supporting the notion that this abundant bacterium have anti-inflammatory effects which might contribute to immune homeostasis in the intestine.
8. Sokol H, Leducq V, Aschard H, *et al.* Fungal microbiota dysbiosis in IBD. *Gut* 2016;
* A recent study showing bacterial and fungal microbiota dysbiosis in IBD suggesting that, beyond bacteria, fungi might also play a role in IBD pathogenesis.
9. Pascal V, Pozuelo M, Borrueal N, *et al.* A microbial signature for Crohn's disease. *Gut* 2017;
*A recent study confirming an alteration in the gut microbial community of IBD patients and suggesting microbiomarkers to discriminate between CD and non-CD patients independently of geographical regions.
10. Liu T-CC, Stappenbeck TS. Genetics and Pathogenesis of Inflammatory Bowel Disease. *Annu Rev Pathol* 2016; 11:127–48.
* A well-done review on recent studies of IBD genetics which contribute to our understanding of the pathogenesis of this disease.
11. Lanternier F, Mahdavian SA, Barbati E, *et al.* Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both. *J Allergy Clin Immunol* 2015; 135:1558–68.e2.
12. Sokol H, Conway KL, Zhang M, *et al.* Card9 mediates intestinal epithelial cell restitution, T-helper 17 responses, and control of bacterial infection in mice. *Gastroenterology* 2013; 145:591–601.e3.
13. Roth S, Bergmann H, Jaeger M, *et al.* Vav Proteins Are Key Regulators of Card9 Signaling for Innate Antifungal Immunity. *Cell Rep* 2016; 17:2572–2583.
* This work contributes to better understand the Card9/NF- κ B pathway leading to cytokines production and participating to antifungal host defense.
14. Roth S, Ruland J. Caspase recruitment domain-containing protein 9 signaling in innate immunity and inflammation. *Trends Immunol* 2013; 34:243–50.
15. Parks OB, Pociask DA, Hodzic Z, *et al.* Interleukin-22 Signaling in the Regulation of Intestinal Health and Disease. *Front Cell Dev Biol* 2015; 3:85.
* State-of-art IL-22 sources, functions and roles in intestinal homeostasis and during several gastrointestinal diseases.
16. Murano T, Okamoto R, Ito G, *et al.* Hes1 promotes the IL-22-mediated antimicrobial response by enhancing STAT3-dependent transcription in human intestinal epithelial cells. *Biochem Biophys Res Commun* 2014; 443:840–6.
17. Lamas B, Richard ML, Leducq V, *et al.* CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. *Nat Med* 2016; 22:598–605.
* The first study reporting an impaired microbial production of AHR ligands in patients with IBD correlated with an IBD-associated SNP within *CARD9*.
18. Spits H, Artis D, Colonna M, *et al.* Innate lymphoid cells--a proposal for uniform nomenclature. *Nat Rev Immunol* 2013; 13:145–9.
19. Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. *Immunol Rev* 2013; 252:116–32.

20. Stockinger B, Meglio P Di, Gialitakis M, Duarte JHH. The aryl hydrocarbon receptor: multitasking in the immune system. *Annu Rev Immunol* 2014; 32:403–32.
 21. Zhou L. AHR Function in Lymphocytes: Emerging Concepts. *Trends Immunol* 2016; 37:17–31.
- **Interesting review on AHR functions in homeostasis and during an immune response.
22. Jostins L, Ripke S, Weersma RK, *et al.* Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 2012; 491:119–24.